as 11-13-2024 4:00pm EST
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
Founded: | 2015 | Country: | United States |
Employees: | N/A | City: | SOUTH SAN FRANCISCO |
Market Cap: | 38.1M | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 30.0K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -16.91 | EPS Growth: | N/A |
52 Week Low/High: | $5.55 - $16.19 | Next Earning Date: | 11-06-2024 |
Revenue: | $10,000,000 | Revenue Growth: | -20.00% |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
SRZN Breaking Stock News: Dive into SRZN Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
GlobeNewswire
8 days ago
GlobeNewswire
10 days ago
GlobeNewswire
2 months ago
Simply Wall St.
3 months ago
GlobeNewswire
3 months ago
GlobeNewswire
5 months ago
PR Newswire
5 months ago
The information presented on this page, "SRZN Surrozen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.